Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy

Abstract Various methods can correct presbyopia, but all require devices or surgeries. Recently, supplements or warming devices to relieve presbyopic symptoms have been developed, but no eye drops have been developed. We screened certain compounds possibly related to lens degeneration and identified...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yukari Tsuneyoshi, Akihiro Higuchi, Kazuno Negishi, Kazuo Tsubota
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8ae2ee3b299441e58924a373dd4666f8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8ae2ee3b299441e58924a373dd4666f8
record_format	dspace
spelling	oai:doaj.org-article:8ae2ee3b299441e58924a373dd4666f82021-12-02T15:06:20ZSuppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy10.1038/s41598-017-07208-62045-2322https://doaj.org/article/8ae2ee3b299441e58924a373dd4666f82017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-07208-6https://doaj.org/toc/2045-2322Abstract Various methods can correct presbyopia, but all require devices or surgeries. Recently, supplements or warming devices to relieve presbyopic symptoms have been developed, but no eye drops have been developed. We screened certain compounds possibly related to lens degeneration and identified pirenoxine, which has been used for cataracts, as a possible new pharmacologic treatment for presbyopia. We first researched the anti-presbyopic activity of pirenoxine in rats. The lens elasticity significantly (p = 0.028) increased with exposure to tobacco smoke for 12 days, and pirenoxine eye drops significantly (p < 0.001) suppressed lens hardening, which causes presbyopia in humans. In a parallel randomized controlled clinical study of the subjects in their fifth decade of life, the objective accommodative amplitude (AA) decreased significantly (p < 0.01) by 0.16 diopter (D) in the control group, and there was no detectable change in the treatment group after a 6-month treatment period, suggesting that pirenoxine eye drops might prevent progression of presbyopia. Subjects in their sixth decade of life, in whom the AA was already nearly 0 D, did not show similar results. Pirenoxine eye drops might be a new and the first pharmacologic treatment for preventing progression of presbyopia.Yukari TsuneyoshiAkihiro HiguchiKazuno NegishiKazuo TsubotaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yukari Tsuneyoshi Akihiro Higuchi Kazuno Negishi Kazuo Tsubota Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy
description	Abstract Various methods can correct presbyopia, but all require devices or surgeries. Recently, supplements or warming devices to relieve presbyopic symptoms have been developed, but no eye drops have been developed. We screened certain compounds possibly related to lens degeneration and identified pirenoxine, which has been used for cataracts, as a possible new pharmacologic treatment for presbyopia. We first researched the anti-presbyopic activity of pirenoxine in rats. The lens elasticity significantly (p = 0.028) increased with exposure to tobacco smoke for 12 days, and pirenoxine eye drops significantly (p < 0.001) suppressed lens hardening, which causes presbyopia in humans. In a parallel randomized controlled clinical study of the subjects in their fifth decade of life, the objective accommodative amplitude (AA) decreased significantly (p < 0.01) by 0.16 diopter (D) in the control group, and there was no detectable change in the treatment group after a 6-month treatment period, suggesting that pirenoxine eye drops might prevent progression of presbyopia. Subjects in their sixth decade of life, in whom the AA was already nearly 0 D, did not show similar results. Pirenoxine eye drops might be a new and the first pharmacologic treatment for preventing progression of presbyopia.
format	article
author	Yukari Tsuneyoshi Akihiro Higuchi Kazuno Negishi Kazuo Tsubota
author_facet	Yukari Tsuneyoshi Akihiro Higuchi Kazuno Negishi Kazuo Tsubota
author_sort	Yukari Tsuneyoshi
title	Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy
title_short	Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy
title_full	Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy
title_fullStr	Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy
title_full_unstemmed	Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy
title_sort	suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/8ae2ee3b299441e58924a373dd4666f8
work_keys_str_mv	AT yukaritsuneyoshi suppressionofpresbyopiaprogressionwithpirenoxineeyedropsexperimentsonratsandnonblindedrandomizedclinicaltrialofefficacy AT akihirohiguchi suppressionofpresbyopiaprogressionwithpirenoxineeyedropsexperimentsonratsandnonblindedrandomizedclinicaltrialofefficacy AT kazunonegishi suppressionofpresbyopiaprogressionwithpirenoxineeyedropsexperimentsonratsandnonblindedrandomizedclinicaltrialofefficacy AT kazuotsubota suppressionofpresbyopiaprogressionwithpirenoxineeyedropsexperimentsonratsandnonblindedrandomizedclinicaltrialofefficacy
_version_	1718388526881439744

Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy

Ejemplares similares